When ever this private company, Concert Pharmaceuticals Inc. does go public, it will be a quick buyout candidate exactly as Sirtris Pharmaceuticals Inc. was, in our opinion. Watch http://www.magenbiosciences.com/ to follow their coporate development as well. We found Sirtris Pharmaceuticals when it was still a private company before it IPO'ed and traded it often making great returns all along. The CEO of Sirtris, which was bought out by Glaxo Smith Kline, is Harvard Phd Christoph Westphal. He is also a founder of Concert Pharmaceuticals as he was with Sirtris, Alnayam pharmaceuticals, Momenta Pharmaceuticals, and Acceleron Pharmaceuticals. All of these firms have become successful businesses and profitable stocks to own. Keep an eye on Concert Pharma's corporate developments here at our website and you will likely be able to make a huge return if you ever decide to invest when they go public.

Concert Named in Top 15 Fierce Biotech Companies:
http://www.concertpharma.com/news/ConcertNamedFierce15BiotechCompany2008.htm
http://www.fiercebiotech.com/special-reports/concert-pharmaceuticals-2008-fierce-15

Christoph Westphal, M.D., Ph.D.

Chief Executive Officer, Sirtris, a GSK Company Christoph Westphal, M.D., Ph.D. co-founded Sirtris Pharmaceuticals, Inc. (formerly NASDAQ:SIRT) and has served as Chief Executive Officer and Vice Chair since 2004. In June of 2008, Sirtris was acquired by GlaxoSmithKline and remains the leader in sirtuin therapeutics for diseases of aging. As CEO and Vice Chair, Dr. Westphal previously co-founded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), and Acceleron Pharmaceuticals. He currently serves on the Board of Directors for Concert Pharmaceuticals, Magen BioSciences, and Harvard Medical School. Dr. Westphal received his M.D. from Harvard Medical School and Ph.D. in Genetics from Harvard University. He graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal was formerly a consultant with McKinsey, and a general partner in a venture capital fund. He has been lead or senior author on several patent applications and papers in journals such as Cell, Nature, and Nature Genetics. Dr. Westphal has received a number of academic and entrepreneurial awards. He is fluent in English, German, Spanish, and French and has visited over 130 countries.